Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML

Publish date:: February 25, 2019

Key clinical point: Midostaurin maintenance therapy after allogeneic stem cell transplant may improve relapse free survival in acute myeloid leukemia with FLT3 expression.

Major finding: Midostaurin maintenance improved relapse-free survival (hazard ratio, 0.46).

Study details: The phase 2 RADIUS trial of 60 patients with acute myeloid leukemia.

Disclosures: Dr. Maziarz reported financial relationships with Incyte, Novartis, Celgene/Juno, Kite/Gilead, Juno Therapeutics, Kite Therapeutics, and Athersys.

Citation:

Transplantation and Cellular Therapy Meetings 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,